Medimmune Limited

Human Genome Sciences, Inc.

Claire Louise Dobson

Karin Von Wachenfeldt

Darren Schofield

Per-Olof Fredrik Eriksson

Craig A Rosen

Steven M Ruben

Tristan J Vaughan

Changshou Gao

Scott A Hammond

Ronald Herbst

Vivian Albert

Godfrey Rainey

Stacey Drabic

Michelle Morrow

Srinath Kasturirangan

Yariv Mazor

Philip Newton

Suzanne E Cohen

Michael Oberst

Brian Lobo

Theodora W Salcedo

Prakash Manikwar

Jonathan Seaman

Simon Dovedi

Gianluca Carlesso

Kristen Pollizzi

Deborah Louise Lane

David Fairman

Sadhana Podichetty

Peter Thornton

Ian Gurrell

Richard Williams

Emma Suzanne Cohen

Maria Groves

Duncan James Cochrane

Phillip David Monk

Steven Godfrey Lane

Vivian R Albert

Yoko Shibata

Ling Huang

Elaine M Hurt

Peter Cariuk

Sudharsan Sridharan

James Button

Fiona Cusdin

John Linley

Margareta Ek

Carina Johansson

Jenny Sandmark

Ann-Charlott Steffen

Martin Schwickart

Wendy A Williams

Clare Jones

Harm Jan Snijder

Tristan John Vaughan

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.

Bispecific binding proteins and uses thereof

The present disclosure is directed to human GDF-15-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect human GDF-15 and/or in methods of treating cancer or body weight loss, including cachexia, associated with over-expression of human GDF-15.

Antibodies directed against GDF-15

The present disclosure provides antibodies and antigen-binding fragments capable of binding PAR2. In some embodiments, the anti-PAR2 antibodies or antigen-binding fragments thereof bind PAR2 in a pH-dependent manner. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.

Nucleic acids encoding anti-PAR2 antibodies and uses thereof

Anti-PAR2 antibodies and uses thereof

The invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.

P2X4 antibodies and uses thereof

Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R&#x3b1;), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R&#x3b1;, IL-4 and/or IL-13, examples of which are asthma and COPD.

Methods for binding members of interleukin-4 receptor &#x3b1; (IL-4R&#x3b1;)

The present invention provides human, humanized and/or chimeric antibodies as well as fragments, derivatives/conjugates and compositions thereof with a specific binding affinity for interleukin-18. The invention includes the use of these antibodies for diagnosing and treating diseases associated with increased IL-18 activity, the latter in the form of a pharmaceutical composition.

Anti-IL-18 antibodies and their uses

Binding members for interleukin-4 receptor alpha (IL-4R&#x3b1;) - 173

Binding members for interleukin-4 receptor alpha (IL-4R&#x3b1;)-173

This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.

Binding members for IgE molecules

The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.

Methods of treating cancer using antibodies that immunospecifically bind to trail receptors

The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.

Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors

Antibodies that immunospecifically bind to trail receptors

Growing community of inventors

Cambridge, United Kingdom

Claire Louise Dobson